文献速递心力衰竭与心肌病心律失常

桥粒斑蛋白心肌病:一种区别于典型扩张型或致心律失常性右室心肌病的纤维炎性心肌病

Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy.
PubMed 文献 · Circulation · 2020-05-06

该研究对比107例致病性DSP突变与81例PKP2突变患者,发现DSP心肌病以左室为主(55% vs 0%,P<0.001),左室心外膜下晚期钆增强常见(40%),且可在收缩功能正常时出现。急性心肌损伤伴肌钙蛋白升高见于15%的DSP患者,并与左室晚期钆增强强相关(90%)。左室射血分数<55%与DSP患者严重室性心律失常强相关(P<0.001)。

要点

  • DSP心肌病以左室受累为主,左室晚期钆增强呈心外膜下分布,可先于收缩功能异常。
  • 急性心肌损伤(胸痛、肌钙蛋白升高、冠脉正常)见于15%的DSP患者,常伴左室晚期钆增强。
  • DSP患者左室射血分数<55%与严重室性心律失常强相关,右室射血分数关联弱。

核心结论

  • DSP心肌病是一种独特的心律失常性心肌病,以发作性心肌损伤、先于收缩功能不全的左室纤维化和高室性心律失常发生率為特征。
  • 应采用基因型特异的诊断和风险分层方法。

研究设计与样本

  • 收集107例致病性DSP突变患者和81例致病性PKP2突变患者的临床与遗传数据作为对照队列。
  • 评估严重室性心律失常的复合终点。

主要发现

  • DSP与PKP2队列的先证者比例相似(41% vs 42%),截短突变比例相似(98% vs 100%)。
  • 左室为主的心肌病仅见于DSP患者(55% vs PKP2 0%,P<0.001);右室心肌病仅见于14%的DSP患者 vs 40%的PKP2患者(P<0.001)。
  • 致心律失常性右室心肌病诊断标准对DSP心肌病敏感性差。
  • 左室晚期钆增强呈主要心外膜下分布见于40%的DSP患者(57例有磁共振图像中23例),其中35%(8/23)左室收缩功能正常。
  • 急性心肌损伤发作(胸痛伴肌钙蛋白升高且冠状动脉造影正常)见于15%的DSP患者,与左室晚期钆增强强相关(90%),即使在心室功能正常的急性心肌损伤中也有4/5(80%)伴晚期钆增强。

关键数值与推荐

  • 左室射血分数<55%对DSP患者严重室性心律失常的敏感性85%、特异性53%(P<0.001)。
  • 右室射血分数<45%与PKP2患者严重心律失常相关(P<0.001),与DSP患者无关(P=0.8)。
  • 左室晚期钆增强见于40%的DSP患者(23/57),其中35%(8/23)左室收缩功能正常。
  • 急性心肌损伤见于15%的DSP患者,与左室晚期钆增强相关(90%)。

临床怎么用

  • 对DSP突变患者应关注左室纤维化(晚期钆增强)和左室射血分数,即使收缩功能正常也需评估心律失常风险。
  • 急性心肌损伤伴肌钙蛋白升高和冠脉正常时,应警惕DSP心肌病,并与心脏结节病或心肌炎鉴别。
  • DSP心肌病的诊断和风险分层不应套用致心律失常性右室心肌病标准,需采用基因型特异方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in desmoplakin (DSP), the primary force transducer between cardiac desmosomes and intermediate filaments, cause an arrhythmogenic form of cardiomyopathy that has been variably associated with arrhythmogenic right ventricular cardiomyopathy. Clinical correlates of DSP cardiomyopathy have been limited to small case series. METHODS: Clinical and genetic data were collected on 107 patients with pathogenic DSP mutations and 81 patients with pathogenic plakophilin 2 (PKP2) mutations as a comparison cohort. A composite outcome of severe ventricular arrhythmia was assessed. RESULTS: DSP and PKP2 cohorts included similar proportions of probands (41% versus 42%) and patients with truncating mutations (98% versus 100%). Left ventricular (LV) predominant cardiomyopathy was exclusively present among patients with DSP (55% versus 0% for PKP2, P<0.001), whereas right ventricular cardiomyopathy was present in only 14% of patients with DSP versus 40% for PKP2 (P<0.001). Arrhythmogenic right ventricular cardiomyopathy diagnostic criteria had poor sensitivity for DSP cardiomyopathy. LV late gadolinium enhancement was present in a primarily subepicardial distribution in 40% of patients with DSP (23/57 with magnetic resonance images). LV late gadolinium enhancement occurred with normal LV systolic function in 35% (8/23) of patients with DSP. Episodes of acute myocardial injury (chest pain with troponin elevation and normal coronary angiography) occurred in 15% of patients with DSP and were strongly associated with LV late gadolinium enhancement (90%), even in cases of acute myocardial injury with normal ventricular function (4/5, 80% with late gadolinium enhancement). In 4 DSP cases with 18F-fluorodeoxyglucose positron emission tomography scans, acute LV myocardial injury was associated with myocardial inflammation misdiagnosed initially as cardiac sarcoidosis or myocarditis. Left ventricle ejection fraction <55% was strongly associated with severe ventricular arrhythmias for DSP cases (P<0.001, sensitivity 85%, specificity 53%). Right ventricular ejection fraction <45% was associated with severe arrhythmias for PKP2 cases (P<0.001) but was poorly associated for DSP cases (P=0.8). Frequent premature ventricular contractions were common among patients with severe arrhythmias for both DSP (80%) and PKP2 (91%) groups (P=non-significant). CONCLUSIONS: DSP cardiomyopathy is a distinct form of arrhythmogenic cardiomyopathy characterized by episodic myocardial injury, left ventricular fibrosis that precedes systolic dysfunction, and a high incidence of ventricular arrhythmias. A genotype-specific approach for diagnosis and risk stratification should be used.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Smith ED, Lakdawala NK, Papoutsidakis N, et al. Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2020. PMID: 32372669. doi:10.1161/CIRCULATIONAHA.119.044934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。